To transform the lives of patients living with autoimmune diseases.
Rapidly advancing a deep portfolio of innovative autoimmune therapeutics that continues to expand through our successful business development strategy.
January 11, 2023
Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)
November 7, 2022